Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2019-12-17, Stock:PFE, The news for the past five days is as follows:
2019-12-10: NEWS1: Dow Jones Today: Stocks Suffered From a Distinct Lack of Excitement.NEWS2: The Daily Biotech Pulse: ASH Meeting Wraps, Fast Track Designation For Equillium, Pfizer To Buy $3M In ContraFect Shares.
2019-12-11: nan
2019-12-12: NEWS1: FDA Approves XELJANZ® XR (tofacitinib) Extended-Release Tablets for the Treatment of Ulcerative Colitis.NEWS2: Iterum Down as Sulopenem Antibiotic Fails in Phase III Study.NEWS3: Big Pharma’s Coming Back in 2020. Don’t Hold Your Breath for Generic Drug Stocks.
2019-12-13: NEWS1: Retired NFL players accused of $3M health benefits scam.NEWS2: Biotech Stocks Burn A Hole In Big Pharma's Pocket; Look For More Mergers In 2020.NEWS3: Dow's 50-point drop led by losses in shares of Verizon Communications Inc., Dow Inc..NEWS4: Jabil (JBL) to Report Q1 Earnings: What's in the Cards?.NEWS5: Sarepta's Vyondys 53 Receives FDA Approval for DMD, Stock Up.NEWS6: Pfizer Receives Positive CHMP Opinion for VYNDAQEL® for Use in Patients with Transthyretin Amyloid Cardiomyopathy, a Rare and Fatal Disease.NEWS7: The Daily Biotech Pulse: Second Time's The Charm For Sarepta, Pfizer's Xeljanz Snags Third Approval, NewLink Genetics Rejects Competing Offer.NEWS8: Pharma Stock Roundup: MRK, SNY to Buy Cancer Firms, LLY Starts New Lung Cancer Study.
2019-12-16: NEWS1: Pfizer stock ticks higher on new FDA approval for prostate cancer drug.NEWS2: US Indexes Close at New Highs Monday.NEWS3: XTANDI® (enzalutamide) Approved by U.S. FDA for the Treatment of Metastatic Castration-Sensitive Prostate Cancer.NEWS4: XTANDI® (enzalutamide) Approved by U.S. FDA for the Treatment of Metastatic Castration-Sensitive Prostate Cancer.NEWS5: Dow Jones Today: Lots of Headlines to Digest.NEWS6: Pfizer Gets CHMP Nod for Vyndaqel Label Expansion in Europe.NEWS7: Amarin’s fish-oil pill now available to millions more patients. But it’s still no Lipitor.NEWS8: Amarin’s Vascepa Approval Seems Fishy for Patients and AMRN Investors.NEWS9: Dow jumps nearly 150 points on gains for Goldman Sachs, Cisco stocks.NEWS10: Pfizer raises dividend by nearly 6%, stock gains.NEWS11: Pfizer Declares First-Quarter 2020 Dividend and Announces Upcoming Investor Day to Highlight Strength of Innovative R&D Pipeline.NEWS12: Lilly's Cyramza Gets CHMP Recommendation for First-Line NSCLC.NEWS13: CFRX: Financing Raises $12 Million, including $3 Million from Pfizer….

Answer: Decrease